Raymond James Boosts ADMA Biologics (NASDAQ:ADMA) Price Target to $25.00

ADMA Biologics (NASDAQ:ADMA) had its target price lifted by Raymond James from $18.00 to $25.00 in a research report sent to investors on Friday,Benzinga reports. Raymond James currently has a strong-buy rating on the biotechnology company’s stock.

ADMA has been the subject of a number of other reports. Cantor Fitzgerald reissued an “overweight” rating and set a $20.00 price objective on shares of ADMA Biologics in a report on Friday, September 20th. HC Wainwright restated a “buy” rating and issued a $18.00 target price on shares of ADMA Biologics in a research note on Monday, October 14th. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, ADMA Biologics presently has a consensus rating of “Buy” and a consensus target price of $21.25.

ADMA Biologics Stock Performance

ADMA stock traded up $2.90 during midday trading on Friday, hitting $22.62. The stock had a trading volume of 9,717,443 shares, compared to its average volume of 3,667,173. The firm has a market capitalization of $5.27 billion, a price-to-earnings ratio of 80.79 and a beta of 0.64. ADMA Biologics has a 52 week low of $3.60 and a 52 week high of $23.52. The stock has a 50-day simple moving average of $18.12 and a 200 day simple moving average of $13.84. The company has a current ratio of 6.87, a quick ratio of 2.80 and a debt-to-equity ratio of 0.74.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings data on Thursday, August 8th. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.08 by $0.05. The company had revenue of $107.20 million during the quarter, compared to analysts’ expectations of $86.44 million. ADMA Biologics had a return on equity of 38.79% and a net margin of 10.53%. The business’s revenue was up 78.4% on a year-over-year basis. During the same period last year, the business earned ($0.02) earnings per share. As a group, equities research analysts anticipate that ADMA Biologics will post 0.49 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Lawrence P. Guiheen sold 9,000 shares of ADMA Biologics stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $18.47, for a total value of $166,230.00. Following the completion of the sale, the director now directly owns 153,941 shares in the company, valued at $2,843,290.27. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other ADMA Biologics news, Director Lawrence P. Guiheen sold 9,000 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $18.47, for a total value of $166,230.00. Following the sale, the director now owns 153,941 shares in the company, valued at approximately $2,843,290.27. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Young Kwon sold 60,000 shares of the business’s stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $18.26, for a total value of $1,095,600.00. Following the completion of the sale, the director now owns 241,441 shares in the company, valued at $4,408,712.66. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 466,900 shares of company stock worth $8,224,121 over the last three months. 3.70% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On ADMA Biologics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Intech Investment Management LLC bought a new stake in shares of ADMA Biologics during the 3rd quarter worth approximately $1,242,000. Jennison Associates LLC bought a new stake in shares of ADMA Biologics during the 3rd quarter worth approximately $690,000. New Millennium Group LLC bought a new stake in shares of ADMA Biologics during the 3rd quarter worth approximately $4,139,000. Aviance Capital Partners LLC bought a new stake in shares of ADMA Biologics during the 3rd quarter worth approximately $229,000. Finally, First Turn Management LLC bought a new stake in shares of ADMA Biologics during the 3rd quarter worth approximately $13,293,000. Institutional investors own 75.68% of the company’s stock.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.